Burrell Terry-Ann
- SEC CIK
- 0001786484
No open-market purchases or sales filed in the past year.
Current role at each company
- RXRX Recursion Pharmaceuticals, Inc.Directoras of Jul 3, 2024
- BEAM Beam Therapeutics Inc.Chief Financial Officeras of Apr 29, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Burrell Terry-Ann as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BEAM Beam Therapeutics Inc.
Chief Financial Officer7 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Burrell Terry-AnnChief Financial Officer | SSale | −5.45K | $32.12 | −$174.9K | −7.2%70.1K after | 10b5-1 |
| Apr 5, 2023 (view filing) | Apr 3-4 | 2 days | Burrell Terry-AnnChief Financial Officer | SSale | −4.64K | $29.74 | −$138.0K | −9.0%47.1K after | 2 lots10b5-1 |
| Jan 30, 2023 (view filing) | Jan 26-27 | 4 days | Burrell Terry-AnnChief Financial Officer | SSale | −37.3K | $45.08 | −$1.68M | −54.4%31.3K after | 2 lots |
| Jan 25, 2023 (view filing) | Jan 23-24 | 2 days | Burrell Terry-AnnChief Financial Officer | SSale | −20.2K | $45.01 | −$910.9K | −39.3%31.3K after | 2 lots |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Burrell Terry-AnnChief Financial Officer | SSale | −47.2K | $45.14 | −$2.13M | −60.1%31.3K after | |
| Apr 4, 2022 (view filing) | Mar 31 | 4 days | Burrell Terry-AnnCFO | SSale | −1.79K | $59.11 | −$105.6K | −4.5%38.3K after | |
| Jul 2, 2021 (view filing) | Jun 30 | 2 days | Burrell Terry-AnnCFO | SSale | −30.0K | $122.00 | −$3.66M | −54.7%24.8K after | 2 lots |
RXRX Recursion Pharmaceuticals, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2023 (view filing) | Jul 12-13 | 2 days | Burrell Terry-AnnDirector | SSaleClass A Common Stock | −117.0K | $12.07 | −$1.41M | −68.1%54.8K after | 5 lots |